Pharmaceutical formulations containing an SGLT2 inhibitor

Details Pharmaceutical formulations containing an SGLT2 inhibitor Pharmaceutical formulations containing an SGLT2 inhibitor

2008-03-21

2010-12-14

Foley, Shanon A (Department: 1619)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C424S451000

Reexamination Certificate

active

07851502

ABSTRACT:
Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrateand a pharmaceutical acceptable carrier therefor, which formulation is designed for immediate release.

REFERENCES:
patent: 6414126 (2002-07-01), Ellsworth et al.
patent: 6515117 (2003-02-01), Ellsworth et al.
patent: 6774112 (2004-08-01), Gougoutas
patent: 7164015 (2007-01-01), Shen et al.
patent: 7375213 (2008-05-01), Deshpande et al.
patent: 2007/0015841 (2007-01-01), Tawa et al.
patent: 2008/0004336 (2008-01-01), Gougoutas et al.
patent: WO 03/099836 (2003-12-01), None
patent: WO 2008/002824 (2008-01-01), None
Meng Wei et al: “Discovery of Dapagliflozin: A potent selective renal sodium-dependent glucose contransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes,” Journal of Medicinal Chemistry, vol. 51, No. 5, Mar. 2008, pp. 1145-1149.

Affiliated with

Also associated with

Rating

Pharmaceutical formulations containing an SGLT2 inhibitor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutical formulations containing an SGLT2 inhibitor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical formulations containing an SGLT2 inhibitor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4223523